^
BIOMARKER:

KMT2D mutation

i
Other names: KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
KMT2D mutation
Squamous Cell Carcinoma of Head and Neck
durvalumab + CP-675206
Sensitive
:
B
KMT2D mutation
Follicular Lymphoma
R-CHOP
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
chidamide
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive
:
C3
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant
:
C3
KMT2D mutation
Colorectal Cancer
Immunotherapy
Sensitive
:
C3
KMT2D mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
KMT2D mutation
Colorectal Cancer
Immunotherapy
Sensitive
:
C3
KMT2D mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive
:
C3
KMT2D mutation
Triple Negative Breast Cancer
cyclophosphamide + epirubicin
Resistant
:
C3
KMT2D mutation
Chronic Lymphocytic Leukemia
decitabine
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
chidamide
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
ibrutinib + chidamide
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
ibrutinib + decitabine
Sensitive
:
D